Long-term dynamics of gastric biomarkers after eradication of Helicobacter pylori infection.

Eur J Gastroenterol Hepatol

aFaculty of Medicine, University of Latvia bDigestive Diseases Centre GASTRO, Faculty of Medicine, University of Latvia, Riga East University Hospital, Riga, Latvia cFaculty of Medicine, Lithuanian University of Health Sciences, Kaunas, Lithuania.

Published: May 2015

Background: Secretion of pepsinogen I (PgI), pepsinogen II (PgII), fasting gastrin-17 (fG-17) and stimulated gastrin-17 (sG-17) changes after Helicobacter pylori eradication. Few data are available on the long-term dynamics of gastric biomarkers after H. pylori eradication.The aim of this study was to investigate the dynamics of gastric biomarkers in H. pylori-positive patients after eradication over a 3-year period and to compare the levels with initially H. pylori-negative patients.

Materials And Methods: Blood samples for the detection of gastric biomarkers were obtained from dyspeptic patients coming for upper gastrointestinal endoscopy. In H. pylori-positive patients, after eradication therapy, three follow-up blood samples were drawn after 12, 24 and 36 months; in H. pylori-negative patients, two samples were taken - at 12 and after 30 months. Median values of biomarkers in follow-up samples were compared with the baseline sample.

Results: The final sample included 110 patients (median age 67 years, M/F ratio 27/83). In patients after H. pylori eradication (n=83) PgI, PgII, fG-17 and sG-17 had decreased significantly during a 36-month period, whereas the PgI/PgII ratio had increased significantly from 5.59 to 11.64.

Conclusion: In H. pylori-positive dyspeptic patients, after eradication therapy, a decrease in PgI, PgII, fG-17 and sG-17 was observed after 36 months whereas an increase in the PgI/II ratio suggested an improvement in gastric atrophy. The median levels of gastric biomarkers in patients after H. pylori eradication therapy may become similar to biomarker levels among initially H. pylori-negative individuals.

Download full-text PDF

Source
http://dx.doi.org/10.1097/MEG.0000000000000308DOI Listing

Publication Analysis

Top Keywords

gastric biomarkers
20
dynamics gastric
12
pylori eradication
12
patients eradication
12
eradication therapy
12
long-term dynamics
8
helicobacter pylori
8
patients
8
pylori-positive patients
8
levels initially
8

Similar Publications

Dysregulated transfer RNA-derived small RNAs as potential gastric cancer biomarkers.

Exp Biol Med (Maywood)

December 2024

Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Nantong University, Nantong, China.

Gastric cancer (GC) is the kind of carcinoma that has the highest rates of morbidity and death worldwide. In the early stages of GC, there is currently an absence of sensitive and specific biomarkers. The newly-discovered class of non-coding RNAs (ncRNAs) known as transfer RNA-derived small RNAs (tsRNAs) is highly expressed in bodily fluids and neoplastic cells.

View Article and Find Full Text PDF

ILF2: a multifaceted regulator in malignant tumors and its prospects as a biomarker and therapeutic target.

Front Oncol

December 2024

Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Interleukin enhancer binding factor 2 (ILF2), formerly called nuclear factor 45 (NF45), is widely expressed in normal human tissues. ILF2 often binds to interleukin enhancer binding factor 3 (ILF3) and regulates gene expression in several ways, participating in multiple DNA and RNA metabolism pathways. Recent studies have shown that ILF2 expression is significantly upregulated in esophageal cancer, lung cancer, gastric cancer, and other malignant tumors, which can promote tumor development and tumor cell proliferation, affect the cell cycle, and induce epithelial-mesenchymal transition.

View Article and Find Full Text PDF

Background: Cancer remains a leading cause of mortality worldwide. A non-invasive screening solution was required for early diagnosis of cancer. Multi-cancer early detection (MCED) tests have been considered to address the challenge by simultaneously identifying multiple types of cancer within a single test using minimally invasive blood samples.

View Article and Find Full Text PDF

Endoscopic ultrasound guided-gastroenterostomy is the best choice in the treatment of gastric outlet obstruction.

World J Gastrointest Endosc

December 2024

Department of General, Gastroenterological and Oncological Surgery, Nicolaus Copernicus University, Toruń 87-100, Kujawsko-Pomorskie, Poland.

First of all, I would like to congratulate Vilas-Boas on an interesting publication. In this letter the authors write about very interesting topics in the management of patients with malignant gastric outlet obstruction (GOO). GOO developed in up to 20% of patients with advanced hepatopancreatobiliary disease both in benign and malignant form.

View Article and Find Full Text PDF

Small cell lung carcinoma metastatic to the stomach: Commonly overlooked, limited treatment options.

World J Gastroenterol

December 2024

Diagnostic and Molecular Pathology, The Ottawa Hospital and University of Ottawa, Ottawa K1H 8L6, Ontario, Canada.

Small cell lung carcinoma metastatic to the stomach, whether synchronous or metachronous, is a rare phenomenon accounting for < 0.5% of lung cancers. Hence it can be overlooked by clinicians resulting in delayed diagnosis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!